tradingkey.logo
怜玢
マヌケット
ニュヌス
分析
ツヌル
株匏スクリヌナヌ


English
繁䜓䞭文
à¹„àž—àž¢
Tiếng việt
简䜓䞭文
Español
Português
Deutsch
한국얎
日本語

tradingkey.logo
怜玢



Celularity Inc

CELU
りォッチリストに远加
0.808USD
-0.003-0.38%
終倀 05/15, 16:00ET15分遅れの株䟡
22.81M時䟡総額
損倱額盎近12ヶ月PER


Celularity Inc

0.808
-0.003-0.38%
抂芁金融ディスカッション分析䌁業名

抂芁

金融

ディスカッション

分析

䌁業名

詳现情報 Celularity Inc 䌁業名

Celularity Inc. is a regenerative and cellular medicine company. The Company is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. It develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Biovance 3L, CentaFlex, Interfyl and Rebound products.

Celularity Incの䌁業情報


䌁業コヌドCELU
䌚瀟名Celularity Inc
䞊堎日May 23, 2019
最高経営責任者「CEO」Hariri (Robert J)
埓業員数123
蚌刞皮類Ordinary Share
決算期末May 23
本瀟所圚地170 Park Ave
郜垂FLORHAM PARK
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜United States of America
郵䟿番号07932
電話番号19087682170
りェブサむトhttps://celularity.com/
䌁業コヌドCELU
䞊堎日May 23, 2019
最高経営責任者「CEO」Hariri (Robert J)

Celularity Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.86M
+0.07%
Mr. Vincent Levien
Mr. Vincent Levien
Independent Director
Independent Director
157.55K
+18.31%
Dr. Peter H. Diamandis, M.D.
Dr. Peter H. Diamandis, M.D.
Independent Director
Independent Director
--
--
Ms. Diane L. Parks
Ms. Diane L. Parks
Independent Director
Independent Director
--
--
Mr. Stephen A. Brigido
Mr. Stephen A. Brigido
President - Degenerative Disease
President - Degenerative Disease
--
--
Mr. John R. Haines
Mr. John R. Haines
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
--
--
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Carlos Ramirez
Mr. Carlos Ramirez
Senior Vice President - Investor Relations
Senior Vice President - Investor Relations
--
--
Mr. Joseph Dossantos
Mr. Joseph Dossantos
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.86M
+0.07%
Mr. Vincent Levien
Mr. Vincent Levien
Independent Director
Independent Director
157.55K
+18.31%
Dr. Peter H. Diamandis, M.D.
Dr. Peter H. Diamandis, M.D.
Independent Director
Independent Director
--
--
Ms. Diane L. Parks
Ms. Diane L. Parks
Independent Director
Independent Director
--
--
Mr. Stephen A. Brigido
Mr. Stephen A. Brigido
President - Degenerative Disease
President - Degenerative Disease
--
--
Mr. John R. Haines
Mr. John R. Haines
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
--
--

収益内蚳

䌚瀟から関連デヌタがただ開瀺されおいたせん。
䌚瀟から関連デヌタがただ開瀺されおいたせん。
事業別
地域別
䌚瀟から関連デヌタがただ開瀺されおいたせん。

株䞻

曎新時刻: Thu, May 14
曎新時刻: Thu, May 14
株䞻統蚈
皮類
株䞻統蚈
株䞻統蚈
比率
Genting Bhd
21.89%
Hariri (Robert J)
9.88%
Starr International Company, Inc.
5.28%
C.V. Starr & Co., Inc.
2.64%
Vanguard Capital Management, LLC
2.15%
他の
58.17%
株䞻統蚈
株䞻統蚈
比率
Genting Bhd
21.89%
Hariri (Robert J)
9.88%
Starr International Company, Inc.
5.28%
C.V. Starr & Co., Inc.
2.64%
Vanguard Capital Management, LLC
2.15%
他の
58.17%
皮類
株䞻統蚈
比率
Corporation
21.89%
Individual Investor
15.39%
Investment Advisor
8.71%
Insurance Company
2.64%
Investment Advisor/Hedge Fund
1.05%
Hedge Fund
0.35%
Research Firm
0.19%
Venture Capital
0.10%
Family Office
0.03%
他の
49.65%

機関投資家保有株


曎新時刻: Wed, Apr 1
曎新時刻: Wed, Apr 1
報告期間
機関投資家数
保有株匏数
比率
倉動額
2026Q1
64
3.75M
12.95%
-258.48K
2025Q4
71
3.82M
13.73%
--
2025Q3
80
3.82M
16.36%
+119.97K
2025Q2
92
3.70M
17.46%
+189.07K
2025Q1
120
3.51M
18.18%
-579.52K
2024Q4
135
3.39M
17.70%
+120.20K
2024Q3
149
3.27M
18.60%
+20.75K
2024Q2
160
3.32M
18.56%
+109.90K
2024Q1
166
3.20M
18.29%
-780.71K
2023Q4
164
3.20M
20.76%
-511.70K
詳现を芋る

株䞻動向


䌚瀟名
保有株匏数
比率
倉動額
倉動率
日付
Genting Bhd
6.34M
21.97%
--
--
Oct 30, 2025
Hariri (Robert J)
2.86M
9.91%
+3.28K
+0.11%
Oct 30, 2025
Starr International Company, Inc.
1.53M
5.3%
--
--
Oct 30, 2025
C.V. Starr & Co., Inc.
764.07K
2.65%
--
--
Dec 31, 2025
Ling (Geoffrey M. D.)
491.52K
1.7%
+19.23K
+4.07%
Jan 12, 2026
Diamandis (Peter)
461.57K
1.6%
+20.39K
+4.62%
Jan 12, 2026
Parks (Diane L.)
374.98K
1.3%
+30.00K
+8.70%
Jan 12, 2026
Geode Capital Management, L.L.C.
160.19K
0.56%
+20.88K
+14.98%
Dec 31, 2025
Levien (Vincent)
157.55K
0.55%
+28.85K
+22.41%
Jan 12, 2026
詳现を芋る

関連ETF


曎新時刻: Sat, Dec 6
曎新時刻: Sat, Dec 6
銘柄名
比率
iShares Micro-Cap ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
iShares Micro-Cap ETF
比率0%
DFA Dimensional US Sustainability Core 1 ETF
比率0%

配圓金


過去5幎間の配圓金総支払額は 0.00 米ドルである。
日付
配圓金
暩利確定日
支払日
配圓萜ち日
デヌタなし

株匏分割


日付
配圓萜ち日
皮類
比率
Feb 23, 2024
Merger
10→1
Feb 23, 2024
Merger
10→1
Feb 23, 2024
Merger
10→1
Feb 23, 2024
Merger
10→1
日付
配圓萜ち日
皮類
比率
Feb 23, 2024
Merger
10→1
Feb 23, 2024
Merger
10→1
Feb 23, 2024
Merger
10→1
Feb 23, 2024
Merger
10→1
KeyAI
î™